Plasmodium Vivax Malaria Clinical Trial
Official title:
A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam
This is a study of drug effectiveness for 2 treatments of vivax malaria, which is one of the
two main types of malaria in Viet Nam. There are two important drugs used in Viet Nam for
treating vivax malaria, Chloroquine and Artemisinin. Sometimes, when medicines are used for
many years they become less effective at treating a disease, especially when they are not
used at adequate doses according to national guidelines or when counterfeit drugs are
available in the market. The purpose of this study is to check that Chloroquine and
Artemisinin, are still effective for patients in Viet Nam.
Participants in this study will be treated with either Dihydroartemisinin-Piperaquine
(DHA-PPQ) or Chloroquine (CQ) for 3 days. Both drugs are recommended by the national
guidelines to treat vivax malaria. The investigators would like to know if both of these
treatments are equally effective so half of the patients in the study will be treated with
DHA-PPQ and the other half will be treated with CQ. This way the investigators can compare
the drugs to find out if one is better than the other.
Participants will be followed for 3 days in hospital, then regularly by follow-up visits
until the 63rd day. Tests will be done to determine the amount of drug and malaria parasites
in the participant's body and how the blood cells react to the malaria. The parasite will be
tested to determine what type it is and how it reacts to the treatment.
The results of the study will be used to inform malaria treatment guidelines in Viet Nam.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04416945 -
Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic
|
N/A | |
| Recruiting |
NCT05052502 -
Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand
|
N/A | |
| Completed |
NCT00295581 -
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
|
Phase 1 | |
| Recruiting |
NCT05788094 -
ACT vs CQ With Tafenoquine for P. Vivax Mono-infection
|
Phase 4 | |
| Completed |
NCT02001428 -
Malaria in Early Life Study
|
N/A | |
| Completed |
NCT02123290 -
DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax
|
Phase 2 | |
| Terminated |
NCT01107145 -
Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)
|
Phase 4 | |
| Terminated |
NCT00138489 -
Papua New Guinean Duffy Negativity And Vivax Malar
|
||
| Not yet recruiting |
NCT04704999 -
Southeast Asia Dose Optimization of Tafenoquine
|
Phase 4 | |
| Completed |
NCT00935623 -
Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans
|
Phase 1 |